KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Shares Outstanding (Weighted Average) (2017 - 2025)

Historic Shares Outstanding (Weighted Average) for Sarepta Therapeutics (SRPT) over the last 11 years, with Q2 2025 value amounting to $98.0 million.

  • Sarepta Therapeutics' Shares Outstanding (Weighted Average) rose 357.97% to $98.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $98.0 million, marking a year-over-year increase of 357.97%. This contributed to the annual value of $81.3 million for FY2021, which is 424.09% up from last year.
  • According to the latest figures from Q2 2025, Sarepta Therapeutics' Shares Outstanding (Weighted Average) is $98.0 million, which was up 357.97% from $95.4 million recorded in Q3 2024.
  • Over the past 5 years, Sarepta Therapeutics' Shares Outstanding (Weighted Average) peaked at $98.0 million during Q2 2025, and registered a low of $79454.0 during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $85.0 million (2021), whereas its average is $62.7 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Shares Outstanding (Weighted Average) crashed by 9989.6% in 2021, and later skyrocketed by 981.57% in 2022.
  • Over the past 5 years, Sarepta Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $81.3 million in 2021, then tumbled by 99.89% to $87253.0 in 2022, then soared by 101775.01% to $88.9 million in 2023, then rose by 7.31% to $95.4 million in 2024, then rose by 2.74% to $98.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $98.0 million for Q2 2025, versus $95.4 million for Q3 2024 and $94.6 million for Q2 2024.